news

FDA announces update to NDMA testing recommendations

4
SHARES

The FDA has released an additional NDMA testing method and has alerted the public to multiple voluntary recalls of ranitidine.

With the US Food and Drug Administration (FDA) conducting investigations into certain ranitidine medicines after they were found to contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels, the agency is now also releasing liquid chromatography-mass spectrometry (LC- MS) as second a method for manufacturers and regulators to detect and quantify these contaminants.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The regulatory body is using this method to test potential NDMA-containing ranitidine samples. The second LC-MS method for NDMA in ranitidine uses a more widely available technology than the first posted method, liquid chromatography-high resolution mass spectrometry (LC-HRMS). The agency is sharing the second method to provide alternatives to firms wishing to test their drug products for NDMA.

The FDA is also alerting health care professionals and patients to two voluntary recalls of ranitidine. The first is Dr Reddy’s Laboratories Ltd is voluntary recall of all prescription and over-the-counter (OTC) ranitidine tablets and capsules manufactured by the company.

The OTC medicines may be labeled by retailers such as Walgreens, Walmart, CVS, Target, and Kroger.

The second is the voluntarily recalling of Sanofi’s OTC ranitidine due to possible NDMA contamination. 

Consumers taking OTC ranitidine, which is used to prevent and relieve heartburn associated with acid indigestion and sour stomach, may consider using other OTC products approved for their condition, the FDA has said.

For updated announcements on ranitidine, visit the FDA’s website.

Share via
Share via